The cancer treatment developer has raised $94m in equity and grant funding, with Pfizer, Celgene and Baxter among its shareholders.
US-based cancer treatment developer Mirna Therapeutics filed for an $80.5m initial public offering on Nasdaq on Monday after securing venture funding from several pharmaceutical companies.
Mirna, which counts Pfizer, Celgene and Baxter among its investors, develops oncology therapeutics based on microRNA technology, which creates mimics of ribonucleic acids that supress tumours.
The company plans to spend up to $65m of the IPO proceeds and cash on hand to fund clinical development expenses for its lead drug candidate, MRX34, advancing it…
